• Cesar Martins da Costa, Zenaide Silva de Souza, Alessandra Corte Real Salgues, Guilherme Harada, Pedro Paulo Marino Rodrigues Ayres, Daniela Bulhões Vieira Nunes, Artur Katz, and Rodrigo Ramella Munhoz.
• Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.
• Immunotherapy. 2020 Oct 1; 12 (15): 1133-1138.

AbstractBackground: Little is known about the 2019 novel coronavirus disease (COVID-19) course and outcomes in patients receiving immunotherapy. Here we describe a metastatic Merkel cell carcinoma patient with a severe acute respiratory syndrome coronavirus 2 infection while receiving pembrolizumab. Case presentation: A 66-year-old man, with a metastatic Merkel cell carcinoma receiving pembrolizumab, presented with fever. Chest computed tomography (CT) showed pulmonary ground-glass opacities, suggesting viral or immuno-related etiology. On day 7, the patient was hospitalized due to dyspnea and worsening of the radiological findings. Real time polymerase chain reaction (RT-PCR) testing confirmed COVID-19. The patient developed acute respiratory distress syndrome and acute kidney injury. Hydroxychloroquine was administered for 5 days, but discontinued after supraventricular extrasystoles. Clinical improvement allowed the patient's discharge after 81 days of hospitalization. Conclusion: A careful evaluation of oncologic patients receiving immunotherapy during the COVID-19 pandemic is of utmost importance.

50 keywords...

hide…